Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anaptysbio (ANAB) Revenue (2016 - 2025)

Anaptysbio (ANAB) has disclosed Revenue for 10 consecutive years, with $108.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 333.0% year-over-year to $108.2 million, compared with a TTM value of $208.3 million through Dec 2025, up 258.18%, and an annual FY2025 reading of $234.6 million, up 157.01% over the prior year.
  • Revenue was $108.2 million for Q4 2025 at Anaptysbio, up from $50.0 million in the prior quarter.
  • Across five years, Revenue topped out at $108.2 million in Q4 2025 and bottomed at $970000.0 in Q1 2022.
  • Average Revenue over 5 years is $16.7 million, with a median of $9.5 million recorded in 2021.
  • The sharpest move saw Revenue plummeted 98.56% in 2021, then soared 422.49% in 2024.
  • Year by year, Revenue stood at $1.0 million in 2021, then surged by 394.56% to $5.0 million in 2022, then surged by 80.1% to $9.0 million in 2023, then soared by 177.62% to $25.0 million in 2024, then surged by 333.0% to $108.2 million in 2025.
  • Business Quant data shows Revenue for ANAB at $108.2 million in Q4 2025, $50.0 million in Q3 2025, and $22.3 million in Q2 2025.